M
Momelotinib
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredient: Momelotinib
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
06/02/2026 Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
The Ministry of Health’s Drug Advisory Committee has recommended:
Momelotinib 100 mg, 150 mg and 200 mg tablets for treating myelofibrosis-related splenomegaly or symptoms in patients with moderate to severe anaemia.
Funding status
[R] Momelotinib 100 mg, 150 mg and 200 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.
Clinical indication, subsidy class and MediShield Life claim limit for momelotinib are provided in the Annex.
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.